Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

CVS Caremark must now shoulder nearly $290 million in damages and penalties after being found complicit in a Medicare Part D ...

Around 16 tons of sausage, pork chops, and ribs made by Sabrositos Hondurenos were recalled for having a false inspection ...

Increased use of GLP-1 and services for cancer and mental health are contributing factors, says Business Group on Health.

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

Approved in June for people at high risk of HIV, Yeztugo was shown to be nearly 100% effective at preventing infection in ...

From rising pharmacy spend to cancer care, 2026 healthcare costs pose new challenges, according to Business Group on Health's ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $284.17, a high ...

Elevance Health and healthcare peers face earnings pressure from rising costs yet offer value with potential growth through ...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...